William N Hait
Affiliation: Johnson and Johnson Pharmaceutical Research and Development
- Anticancer drug development: the grand challengesWilliam N Hait
Ortho Biotech Oncology Research and Development, 920 Route 202, Raritan, New Jersey 08869, USA
Nat Rev Drug Discov 9:253-4. 2010..What are the key challenges in anticancer drug development, and how might they be addressed?..
- Forty years of translational cancer researchWilliam N Hait
Janssen, The Pharmaceutical Companies of Johnson and Johnson, Raritan, NJ 08869, USA
Cancer Discov 1:383-90. 2011....
- Targeted cancer therapeuticsWilliam N Hait
Division of Johnson and Johnson, Ortho Biotech Oncology Research and Development, Raritan, New Jersey 08869, USA
Cancer Res 69:1263-7; discussion 1267. 2009..Finally, a detailed understanding of the target's structure and function will help anticipate and identify mechanism of drug resistance and help design drugs and combinations of drugs that retain activity...
- AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug developmentSamir N Khleif
National Cancer Institute, Raritan, New Jersey, USA
Clin Cancer Res 16:3299-318. 2010....